Patents Assigned to Leiden University (Medical Center)
-
Publication number: 20220041928Abstract: New methods and assays for multiplexed detection of analytes using phosphors that are uniform in morphology, size, and composition based on their unique optical lifetime signatures are described herein. The described assays and methods can be used for imaging or detection of multiple unique chemical or biological markers simultaneously in a single assay readout.Type: ApplicationFiled: July 7, 2021Publication date: February 10, 2022Applicants: INTELLIGENT MATERIAL SOLUTIONS, INC., LEIDEN UNIVERSITY MEDICAL CENTER, U.S.A , AS REPRESENTED BY THE SECRETARY, OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Howard Y. BELL, Joshua E. Collins, Paul L.A.M. Corstjens, Sukwan Handali, Hans J. Tanke
-
Patent number: 11077131Abstract: The disclosure is based on the finding that compounds capable of binding to (or interacting with) chromatin binding/remodelling complexes (for example Polycomb group PRC1 and Trithorax group MLL) and/or modulation of the same can be used to modulate (for example switch on/off) ciliogenesis as may occur, for example, in the human pulmonary bronchial epithelium. Provided are compounds, compositions, methods and medicaments which may be used to treat and/or prevent diseases and/or conditions associated with aberrant or defective ciliogenesis.Type: GrantFiled: November 17, 2016Date of Patent: August 3, 2021Assignee: Academisch Ziekenhuis Leiden a/u Leiden University Medical CenterInventor: Ronald Karel Louisa Van Brempt
-
Publication number: 20210198739Abstract: In one aspect, the invention provides a method of screening a human subject to determine if said subject has a genetic predisposition to develop, or is suffering from Facioscapulohumeral Dystrophy (FSHD), said method comprising: (a) providing a biological sample comprising genomic DNA from the subject; and (b) analyzing the portion of the genomic DNA in the sample corresponding to the distal D4Z4-pLAM region on chromosome 4 and determining the presence or absence of a polymorphism resulting in a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene.Type: ApplicationFiled: December 7, 2020Publication date: July 1, 2021Applicants: Fred Hutchinson Cancer Research Center, University of Rochester, Leiden University Medical CenterInventors: Silvere M. van der Maarel, Stephen J. Tapscott, Rabi Tawil, Richard J.L.F. Lemmers, Linda Geng, Laura Snider
-
Patent number: 10865445Abstract: In one aspect, the invention provides a method of screening a human subject to determine if said subject has a genetic predisposition to develop, or is suffering from Facioscapulohumeral Dystrophy (FSHD), said method comprising: (a) providing a biological sample comprising genomic DNA from the subject; and (b) analyzing the portion of the genomic DNA in the sample corresponding to the distal D4Z4-pLAM region on chromosome 4 and determining the presence or absence of a polymorphism resulting in a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene, wherein a determination of the absence of a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene indicates that the subject does not have a genetic predisposition to develop, and is not suffering from FSHD, and/or wherein a determination of the presence of a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene indicates that the subject has a genetic predisposition to develType: GrantFiled: August 18, 2011Date of Patent: December 15, 2020Assignees: Fred Hutchinson Cancer Research Center, University of Rochester, Leiden University Medical CenterInventors: Silvere M. van der Maarel, Stephen J. Tapscott, Rabi Tawil, Richard J. L. F. Lemmers, Linda Geng, Lauren Snider
-
Patent number: 10837058Abstract: An in vitro method for screening for candidate compounds for preventing and/or attenuating skin ageing, and/or hydrating skin, includes: a) contacting a test compound with a sample of papillary fibroblasts; b) measuring the expression of a gene selected from PDPN, CCRL1 and NTN1, in the papillary fibroblasts; and c) selecting compounds for which an activation of at least 1.5 fold of the expression of at least one of the genes is measured in the treated papillary fibroblasts compared with untreated papillary fibroblasts. Another in vitro method includes: a) contacting a test compound with a sample of reticular fibroblasts; b) measuring the expression of a gene selected from MGP, PPP1R14A and TGM2, in the reticular fibroblasts; and c) selecting compounds for which an activation of at most 1.0 fold of the expression of at least one of the genes is measured in the treated reticular fibroblasts compared with untreated reticular fibroblasts.Type: GrantFiled: November 23, 2012Date of Patent: November 17, 2020Assignees: CHANEL PARFUMS BEAUTE, LEIDEN UNIVERSITY MEDICAL CENTERInventors: Gaelle Saintigny, Abdelouahab Elghalbzouri
-
Patent number: 10684284Abstract: The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.Type: GrantFiled: October 23, 2017Date of Patent: June 16, 2020Assignees: Inova Diagnostics, Inc., Leiden University Medical CenterInventors: Michael Mahler, Leendert A. Trouw, Jan Wouter Drijfhout, Tom Huizinga, René Toes, Peter Van Veelen
-
Patent number: 10189880Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.Type: GrantFiled: November 2, 2015Date of Patent: January 29, 2019Assignee: LEIDEN UNIVERSITY MEDICAL CENTERInventors: Mirjam H. M. Heemskerk, J. H. Frederik Falkenburg
-
Publication number: 20190023984Abstract: New methods and assays for multiplexed detection of analytes using phosphors that are uniform in morphology, size, and composition based on their unique optical lifetime signatures are described herein. The described assays and methods can be used for imaging or detection of multiple unique chemical or biological markers simultaneously in a single assay readout.Type: ApplicationFiled: August 7, 2018Publication date: January 24, 2019Applicants: INTELLIGENT MATERIAL SOLUTIONS, INC., LEIDEN UNIVERSITY MEDICAL CENTER, United States of America, as Represented by the Secretary,of the Dept of health and Human ServicesInventors: Howard Y. BELL, Joshua E. COLLINS, Paul L.A.M. CORSTJENS, Sukwan HANDALI, Hans J. TANKE
-
Patent number: 10058516Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.Type: GrantFiled: January 28, 2016Date of Patent: August 28, 2018Assignees: University of Maryland Baltimore County, Katholieke Universiteit Leuven, Leiden University Medical CenterInventors: Katherine L. Radtke, Hannah L. Peters, Johan Neyts, Dirk Jochmans, Eric J. Snijder
-
Patent number: 10054593Abstract: New methods and assays for multiplexed detection of analytes using phosphors that are uniform in morphology, size, and composition based on their unique optical lifetime signatures are described herein. The described assays and methods can be used for imaging or detection of multiple unique chemical or biological markers simultaneously in a single assay readout.Type: GrantFiled: June 6, 2016Date of Patent: August 21, 2018Assignees: INTELLEIGENT MATERIAL SOLUTIONS, INC., LEIDEN UNIVERSITY MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Howard Y. Bell, Joshua E. Collins, Paul L. A. M. Corstjens, Sukwan Handali, Hans J. Tanke
-
Publication number: 20180216060Abstract: The invention relates to the utilization of specific cell surface biomarkers (preferably cell specific receptors) to generate a reversible layer-by-layer scaffold for the functionalization of cells. The cells of the present invention can be used in a wide variety of distinct applications, including cellular targeting, imaging, drug delivery, purification, cell sensing, diagnosis and waste stream/body fluid purification.Type: ApplicationFiled: July 15, 2016Publication date: August 2, 2018Applicant: ACADEMISCH ZIEKENHUIS LEIDEN (ALSO ACTING UNDER TH E NAME OF LEIDEN UNIVERSITY MEDICAL CENTER)Inventors: Fijs Willem Bernhard VAN LEEUWEN, Marcus Theodorus Maria ROOD
-
Patent number: 9999660Abstract: The present invention is directed to polypeptides and compositions thereof useful for the prevention and treatment of allergic disorders, in particular atopic asthma. More particularly, the invention relates to tolerogenic agents and compositions thereof that are useful for the prevention and treatment of hypersensitivity to allergens, in particular strategies of desensitization to allergens.Type: GrantFiled: January 30, 2015Date of Patent: June 19, 2018Assignees: UNIVERSITAT ZURICH, LEIDEN UNIVERSITY MEDICAL CENTERInventors: Anne Mueller, Daniela Engler-Anders, Christian Taube
-
Patent number: 9829489Abstract: The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.Type: GrantFiled: July 22, 2015Date of Patent: November 28, 2017Assignees: INOVA DIAGNOSTICS, INC., LEIDEN UNIVERSITY MEDICAL CENTERInventors: Michael Mahler, Leendert A Trouw, Jan Wouter Drijfhout, Tom Huizinga, René Toes, Peter Van Veelen
-
Patent number: 9574015Abstract: Agents, compositions, and medicaments that reduce interactions between muscle specific kinase receptor (MuSK) and pathogenic immunoglobulin G4 (IgG4) antibodies specific for the first Ig-like domain of MuSK and methods and uses thereof to reduce such interactions are encompassed herein. Also encompassed are screening assays to identify inhibitors of these pathogenic antibodies, particularly those that reduce binding to MuSK. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to improve motor function in subjects afflicted MuSK-MG.Type: GrantFiled: September 15, 2014Date of Patent: February 21, 2017Assignees: New York University, Leiden University Medical CenterInventors: Steven J. Burden, Wei Zhang, Maartje Huijbers, Johannes J. Verschuuren, Silvère M. van der Maarel
-
Publication number: 20150313988Abstract: The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes.Type: ApplicationFiled: September 25, 2013Publication date: November 5, 2015Applicants: UNIVERSITY OF MANITOBA, LEIDEN UNIVERSITY MEDICAL CENTERInventors: Marjolein Kikkert, Paul Bertyne van Kasteren, Eric John Snijder, Brian Leonard Mark, Terrence William James
-
Patent number: 9078895Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: GrantFiled: December 5, 2013Date of Patent: July 14, 2015Assignees: St. Jude Children's Research Hospital, Flanders Interuniversity Institute for Biotechnology, Universiteit Gent, Leiden University Medical CenterInventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
-
Publication number: 20140323345Abstract: An in vitro method for screening for candidate compounds for preventing and/or attenuating skin ageing, and/or hydrating skin, includes: a) contacting a test compound with a sample of papillary fibroblasts; b) measuring the expression of a gene selected from PDPN, CCRL1 and NTN1, in the papillary fibroblasts; and c) selecting compounds for which an activation of at least 1.5 fold of the expression of at least one of the genes is measured in the treated papillary fibroblasts compared with untreated papillary fibroblasts. Another in vitro method includes: a) contacting a test compound with a sample of reticular fibroblasts; b) measuring the expression of a gene selected from MGP, PPP1R14A and TGM2, in the reticular fibroblasts; and c) selecting compounds for which an activation of at most 1.0 fold of the expression of at least one of the genes is measured in the treated reticular fibroblasts compared with untreated reticular fibroblasts.Type: ApplicationFiled: November 23, 2012Publication date: October 30, 2014Applicants: LEIDEN UNIVERSITY MEDICAL CENTER, CHANEL PARFUMS BEAUTEInventors: Gaelle Saintigny, Abdelouahab Elghalbzouri
-
Publication number: 20140121218Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: ApplicationFiled: December 5, 2013Publication date: May 1, 2014Applicants: St. Jude Children's Research Hospital, Leiden University Medical Center, Universiteit Gent, Flanders Interuniversity Institute for Biotechnology VIBInventors: Michael A. Dyer, Jean-Christopher Marine, Aart Gerrit Jochemsen
-
Patent number: 8614192Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: GrantFiled: July 24, 2007Date of Patent: December 24, 2013Assignees: Leiden University Medical Center, Flanders Interuniversity Institute for Biotechnology, VIB, St. Jude Children's Research HospitalInventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
-
Publication number: 20130316463Abstract: A method of purifying a glycan and/or a glycoconjugate comprising the steps of: (a) providing a stationary phase that comprises cotton; (b) applying a glycan and/or glycoconjugate-containing sample to the stationary phase; (c) washing the stationary phase with a first solvent; and (d) eluting the glycan and/or glycoconjugate from the stationary phase with a second solvent. A kit for purifying a glycan and/or glycoconjugate, the kit comprising: a stationary phase comprising cotton; and instructions for purifying a glycan and/or glycoconjugate according to the disclosed method.Type: ApplicationFiled: February 10, 2012Publication date: November 28, 2013Applicants: F. HOFFMAN-LA ROCHE AG, LEIDEN UNIVERSITY MEDICAL CENTERInventors: Manfred Wuhrer, Mahdi Hemayatkar, Maurice Henricus Johannes Selman